Telix Pharmaceuticals Limited ADR (TLX) Stock Price, Quote & News

Company Profile

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250...

Industry: Biotechnology

Sector: Healthcare

Phone: 61 3 9093 3855

Website: telixpharma.com

Address:

55 Flemington Road, Level 4, North Melbourne, Australia

RadioIsotope25 Aug. 3 at 1:14 PM

$RADX Now that Lantheus is acquired hopefully Curium is focused on $RADX now $LNTH $TLX

0 · Reply

Merlintrader Aug. 2 at 3:38 PM

The Top Ten Biotech Stocks Right Now — updated for August with upcoming catalysts, clinical readouts, cash runway and key risks. Four names in focus: $RARE $PHVS $SLS $TLX Full ranked watchlist: https://www.merlintrader.com/top-ten-biotech-stocks-right-now/

1 · Reply

JustBen47 Jul. 28 at 12:16 AM

$TLX Prostate cancer is one of the most commonly diagnosed cancers globally. PSMA PET imaging is becoming increasingly important for detecting and staging prostate cancer, creating a significant market opportunity. .

0 · Reply

Merlintrader Jul. 27 at 3:17 PM

$SLS $TLX $REPL $EYPT

0 · Reply

Merlintrader Jul. 25 at 5:36 PM

$SLS $TLX $REPL $EYPT The Top Ten Biotech Stocks Right Now https://www.merlintrader.com/top-ten-biotech-stocks-right-now/

0 · Reply

Aleexandder Jul. 24 at 9:36 PM

$TLX Strong revenue growth. In its latest quarterly update, the company reported US$247 million in Q2 revenue, up 21% year over year..

0 · Reply

topstockalerts Jul. 21 at 2:12 AM

Telix Pharmaceuticals shares rose after the company reported strong second-quarter results and provided an upbeat outlook for 2026. Revenue reached $247 million in the June quarter, up 7% sequentially and 21% year over year, driven by 30% annual growth in its Precision Medicine segment, which generated $202 million in revenue. Management now expects full-year 2026 revenue and other income to exceed $1 billion, targeting the upper end of its previous guidance range of $950 million to $970 million, plus $40 million in non-reimbursable income from Regeneron. The company also announced that the first patient has been dosed in its Phase 3 LUTEON trial evaluating TLX250-Tx for recurrent clear cell renal cell carcinoma, marking the first Phase 3 study of a carbonic anhydrase IX-targeted radiopharmaceutical therapy. Additionally, Telix raised its 2026 R&D spending guidance to between $230 million and $270 million to support accelerated investments in high-value clinical programs. $TLX $REGN

0 · Reply

STACKD0E Jul. 20 at 10:56 PM

$PAPL $INFQ $TLX ✨️

0 · Reply

prismmarketview Jul. 17 at 1:01 PM

$TLX Telix Pharma has finished enrolling 105 pts in the Illuccix Japan Phase 3 study for TLX591‑Px prostate cancer imaging. Big operational milestone as the company targets approval in a top nuclear medicine market. #TLX #Illuccix #radiopharma https://prismmarketview.com/illuccix-japan-study-hits-full-enrollment-as-telix-moves-closer-to-prostate-cancer-imaging-approval/

0 · Reply

prismmarketview Jul. 16 at 12:48 PM

#Telix ($TLX ) is quietly moving PSMA RLT upstream. TLX597‑Tx, its next‑gen radioligand, is now in the OPTIMAL‑e Phase 2 trial in metastatic hormone‑sensitive prostate cancer — aiming for lower organ exposure, higher tumor uptake, and earlier, more durable control vs waiting for salvage mCRPC. #TLX #Biotech #Oncology #ProstateCancer #RadioligandTherapy https://prismmarketview.com/moves-upstream-telixs-optimal-e-targets-earlier-prostate-cancer/

0 · Reply

Market Cap	3.36B
Revenue (ttm)	803.79M
Net Income (ttm)	-7.13M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	218.70
Profit Margin	-0.89%
Debt to Equity Ratio	0.98

Volume	121,700
Avg Vol	173,256
Day's Range	N/A - N/A
Shares Out	339.78M
Stochastic %K	29%
Beta	-0.31
Analysts	Strong Sell
Price Target	$20.33